CagriSema (cagrilintide-semaglutide): Complete Guide 2026
CagriSema is an investigational once-weekly combination injection of cagrilintide (an amylin analog) and semaglutide (a GLP-1 receptor agonist) being developed by Novo Nordisk. By targeting two distinct hormonal pathways — amylin and GLP-1 — CagriSema aims to deliver superior weight loss compared to semaglutide alone. Phase 3 REDEFINE trials have shown approximately 24-25% weight loss, potentially making it the most effective injectable anti-obesity therapy if approved. CagriSema is not yet approved by any regulatory agency.
Enzo's Tip
CagriSema is the ultimate tag team — two hormones working together like Enzo and his best cat buddy tackling a cardboard box from both sides! This one's still in clinical trials, so you can't get it yet, but Enzo is keeping his whiskers perked for approval day! 🧪🐱
Track your CagriSema journey with Enzo
Dose tracking, side effect logging, and a cute cat cheering you on. Free to download.
Quick Facts
| Generic Name | cagrilintide-semaglutide |
| Manufacturer | Novo Nordisk |
| Type | Injectable pen |
| Frequency | Once weekly |
| Primary Indication | Chronic weight management |
CagriSema Guides
Enzo reminds you when your next CagriSema dose is due
Dose tracking, side effect logging, and a cute cat cheering you on. Free to download.
Frequently Asked Questions
The guide your doctor doesn't have time to give you
Your complete CagriSema playbook: week-by-week guide, what to eat when nothing sounds good, and how to manage every side effect. Free.
No spam. Unsubscribe anytime.
Medical Disclaimer: Enzo is a tracking companion, not a doctor. Always consult your healthcare provider before starting, stopping, or changing any medication. The information on this page is for educational purposes only and should not be considered medical advice. Individual results may vary.